Annuncio • Jul 28
InfuSystem Holdings, Inc. to Report Q2, 2026 Results on Aug 04, 2026 InfuSystem Holdings, Inc. announced that they will report Q2, 2026 results Pre-Market on Aug 04, 2026 Recent Insider Transactions Derivative • May 27
President exercised options and sold US$67k worth of stock On the 18th of May, Carrie Lachance exercised options to acquire 8k shares at no cost and sold these for an average price of US$8.83 per share. This trade did not impact their existing holding. For the year to December 2019, Carrie's total compensation was 16% salary and 84% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since September 2025, Carrie's direct individual holding has increased from 232.17k shares to 238.12k. Company insiders have collectively sold US$112k more than they bought, via options and on-market transactions in the last 12 months. New Risk • May 22
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 20% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • May 20
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to US$10.16, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 17x in the Healthcare industry in the US. Total returns to shareholders of 15% over the past three years. Annuncio • May 19
InfuSystem Holdings, Inc. (NYSEAM:INFU) announces an Equity Buyback for $20 million worth of its shares. InfuSystem Holdings, Inc. (NYSEAM:INFU) announces a share repurchase program. Under the program, the company will repurchase up to $20 million worth of its outstanding common shares. The program will be valid till June 30, 2028. Reported Earnings • May 11
First quarter 2026 earnings: EPS exceeds analyst expectations while revenues lag behind First quarter 2026 results: EPS: US$0.05 (up from US$0.013 loss in 1Q 2025). Revenue: US$33.7m (down 3.0% from 1Q 2025). Net income: US$1.02m (up US$1.28m from 1Q 2025). Profit margin: 3.0% (up from net loss in 1Q 2025). The move to profitability was driven by lower expenses. Revenue missed analyst estimates by 1.9%. Earnings per share (EPS) exceeded analyst estimates by 47%. Revenue is forecast to grow 5.9% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 95% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Annuncio • Apr 30
InfuSystem Holdings, Inc. to Report Q1, 2026 Results on May 07, 2026 InfuSystem Holdings, Inc. announced that they will report Q1, 2026 results Pre-Market on May 07, 2026 Annuncio • Apr 13
InfuSystem Holdings, Inc., Annual General Meeting, May 11, 2026 InfuSystem Holdings, Inc., Annual General Meeting, May 11, 2026. Location: meetnow.global/mcc9pvy, United States Valuation Update With 7 Day Price Move • Mar 03
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to US$9.29, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 17x in the Healthcare industry in the US. Total loss to shareholders of 3.0% over the past three years. Reported Earnings • Feb 24
Full year 2025 earnings: EPS exceeds analyst expectations Full year 2025 results: EPS: US$0.32 (up from US$0.11 in FY 2024). Revenue: US$143.4m (up 6.4% from FY 2024). Net income: US$6.63m (up 183% from FY 2024). Profit margin: 4.6% (up from 1.7% in FY 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 6.9%. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 4.9% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 101% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Annuncio • Feb 17
InfuSystem Holdings, Inc. to Report Q4, 2025 Results on Feb 24, 2026 InfuSystem Holdings, Inc. announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Feb 24, 2026 Annuncio • Dec 11
Ambulatory Infusion Pumps used in Pain Management Business by InfuSystem Holdings, Inc. to Receive Separate Payment Under NOPAIN Act Starting January 1, 2026 InfuSystem Holdings, Inc. announced that the Centers for Medicare and Medicaid Services (‘CMS’) has added two of the electronic infusion pumps currently utilized by the Company within its Pain Management services business to the list of qualifying products for separate payment in conjunction with the Non-Opioids Prevent Addiction in the Nation (‘NOPAIN’) Act. The NOPAIN Act mandates that CMS provide separate payment for qualified non-opioid treatments through December 31, 2027 when provided with a covered surgical procedure. This payment may now be available to InfuSystem’s current and potential Pain Management customers for certain patients. This initiative is part of a broader strategy by CMS to combat the opioid crisis by promoting safer pain management alternatives. The two pumps are the CADD-Solis manufactured by ICU Medical, Inc., and Eitan Medical’s Sapphire pump. The New Rule:On November 25, 2025, CMS issued its final Medicare Hospital Outpatient Prospective Payment System (OPPS) and Medicare Ambulatory Surgical Center (ASC) Payment System rule for 2026. This rule, effective January 1, 2026, implements the NOPAIN Act that mandates separate Medicare payment for qualifying non-opioid drugs and devices. The NOPAIN Act, passed as part of the Consolidated Appropriation Act of 2023, aims to increase patient access to non-opioid drugs and devices used to manage pain in Hospital Outpatient (HOPD) and ASC settings by providing additional Medicare reimbursement for qualifying non-opioid items. In the final rule, CMS confirmed that the CADD-Solis infusion pump manufactured by ICU Medical, and used by InfuSystem for the majority of its Pain Management services business, and Eitan Medical’s Sapphire Infusion Pump, meet qualifying requirements, making them eligible for separate payment under the NOPAIN Act. HOPDs and ASCs that use these products will receive separate Medicare reimbursement in addition to the related APC payments beginning January 1, 2026. Both the CADD-Solis infusion pump and the Sapphire Infusion pump received a unique, brand-specific Healthcare Common Procedure Coding System (HCPCS) code eligible for separate payment in the HOPD and ASC settings. This decision by CMS is a pivotal step towards enhancing access to clinically proven non-opioid treatments for Medicare beneficiaries in HOPD and ASC settings. The payment limitation calculated and published by CMS is up to $1,997.16. The new unique HCPCS code C9815 for the CADD-Solis Infusion pump and C9811 for Eitan’s Sapphire pump can be used on claim submissions for services rendered beginning on January 1, 2026. The NOPAIN Act mandates that CMS provide separate payment for qualified non-opioid treatments through December 31, 2027 when provided with a covered surgical procedure. The CADD-Solis and Sapphire infusion pumps will now accompany other ambulatory infusion pain pumps previously included under this policy, which aims to reduce reliance on opioids in postoperative care. CMS will review and approve eligible products on an annual basis during the 3-year program. This initiative is part of a broader strategy by CMS to combat the opioid crisis by promoting safer pain management alternatives. New Risk • Nov 07
New minor risk - Financial position The company has a high level of debt. Net debt to equity ratio: 47% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Minor Risks High level of debt (47% net debt to equity). Significant insider selling over the past 3 months (US$56k sold). Reported Earnings • Nov 04
Third quarter 2025 earnings: EPS exceeds analyst expectations Third quarter 2025 results: EPS: US$0.11 (up from US$0.085 in 3Q 2024). Revenue: US$36.5m (up 3.3% from 3Q 2024). Net income: US$2.26m (up 25% from 3Q 2024). Profit margin: 6.2% (up from 5.1% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 38%. Revenue is forecast to grow 8.2% p.a. on average during the next 3 years, compared to a 5.4% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 102% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Annuncio • Oct 29
InfuSystem Holdings, Inc. to Report Q3, 2025 Results on Nov 04, 2025 InfuSystem Holdings, Inc. announced that they will report Q3, 2025 results Pre-Market on Nov 04, 2025 Recent Insider Transactions • Aug 28
Director recently sold US$56k worth of stock On the 22nd of August, Scott Shuda sold around 6k shares on-market at roughly US$9.67 per share. This transaction amounted to 5.8% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought US$45k more than they sold in the last 12 months. Recent Insider Transactions • Aug 25
Director recently sold US$56k worth of stock On the 22nd of August, Scott Shuda sold around 6k shares on-market at roughly US$9.67 per share. This transaction amounted to 5.8% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought US$45k more than they sold in the last 12 months. Recent Insider Transactions Derivative • Aug 24
Director notifies of intention to sell stock Scott Shuda intends to sell 6k shares in the next 90 days after lodging an Intent To Sell Form on the 22nd of August. If the sale is conducted around the recent share price of US$9.81, it would amount to US$56k. Since December 2024, Scott has owned 101.99k shares directly. Company insiders have collectively sold US$241k more than they bought, via options and on-market transactions in the last 12 months. Valuation Update With 7 Day Price Move • Aug 13
Investor sentiment improves as stock rises 30% After last week's 30% share price gain to US$9.32, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 13x in the Healthcare industry in the US. Total returns to shareholders of 17% over the past three years. Major Estimate Revision • Aug 12
Consensus EPS estimates increase by 82%, revenue downgraded The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from US$146.9m to US$144.2m. EPS estimate rose from US$0.14 to US$0.255. Net income forecast to grow 35% next year vs 23% growth forecast for Healthcare industry in the US. Consensus price target broadly unchanged at US$13.75. Share price rose 55% to US$9.43 over the past week. Reported Earnings • Aug 05
Second quarter 2025 earnings: EPS exceeds analyst expectations Second quarter 2025 results: EPS: US$0.13 (up from US$0.034 in 2Q 2024). Revenue: US$36.0m (up 6.8% from 2Q 2024). Net income: US$2.60m (up 263% from 2Q 2024). Profit margin: 7.2% (up from 2.1% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates. Revenue is forecast to grow 8.2% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Annuncio • Aug 05
InfuSystem Holdings, Inc. Updates Earnings Guidance for the Full Year 2025 InfuSystem Holdings, Inc. updated earnings guidance for the full year 2025. For the year, the company net revenue growth estimated to be in the 6% to 8% range. The prior net revenue growth range was 8% to 10%. Annuncio • Jul 30
InfuSystem Holdings, Inc. to Report Q2, 2025 Results on Aug 05, 2025 InfuSystem Holdings, Inc. announced that they will report Q2, 2025 results at 9:30 AM, US Eastern Standard Time on Aug 05, 2025 Price Target Changed • Jul 22
Price target decreased by 9.0% to US$13.50 Down from US$14.83, the current price target is an average from 4 analysts. New target price is 135% above last closing price of US$5.75. Stock is down 17% over the past year. The company is forecast to post earnings per share of US$0.14 for next year compared to US$0.11 last year. Valuation Update With 7 Day Price Move • Jun 03
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to US$6.06, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 13x in the Healthcare industry in the US. Total loss to shareholders of 40% over the past three years. Recent Insider Transactions Derivative • May 21
Chief Executive Officer exercised options and sold US$120k worth of stock On the 17th of May, Richard DiIorio exercised options to acquire 20k shares at no cost and sold these for an average price of US$6.15 per share. This trade did not impact their existing holding. For the year to December 2018, Richard's total compensation was 25% salary and 75% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since June 2024, Richard's direct individual holding has decreased from 455.77k shares to 423.68k. Company insiders have collectively sold US$293k more than they bought, via options and on-market transactions in the last 12 months. Major Estimate Revision • May 15
Consensus EPS estimates fall by 25% The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate fell from US$0.20 to US$0.15 per share. Revenue forecast steady at US$146.9m. Net income forecast to grow 25% next year vs 21% growth forecast for Healthcare industry in the US. Consensus price target of US$13.63 unchanged from last update. Share price rose 4.8% to US$5.73 over the past week. Price Target Changed • May 13
Price target decreased by 8.1% to US$13.63 Down from US$14.83, the current price target is an average from 4 analysts. New target price is 137% above last closing price of US$5.75. Stock is down 17% over the past year. The company is forecast to post earnings per share of US$0.15 for next year compared to US$0.11 last year. Reported Earnings • May 09
First quarter 2025 earnings: EPS and revenues exceed analyst expectations First quarter 2025 results: US$0.013 loss per share (improved from US$0.052 loss in 1Q 2024). Revenue: US$34.7m (up 8.5% from 1Q 2024). Net loss: US$267.0k (loss narrowed 76% from 1Q 2024). Revenue exceeded analyst estimates by 2.8%. Earnings per share (EPS) also surpassed analyst estimates by 67%. Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 7.0% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 94% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • May 08
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to US$5.47, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 14x in the Healthcare industry in the US. Total loss to shareholders of 34% over the past three years. Annuncio • May 08
InfuSystem Holdings, Inc. Reaffirms Earnings Guidance for the Full Year 2025 InfuSystem Holdings, Inc. reaffirmed earnings guidance for the full year 2025. For the year, the company net revenue growth estimated to be in the 8% to 10% range. New Risk • May 01
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: US$99.2m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks High level of debt (41% net debt to equity). Market cap is less than US$100m (US$99.2m market cap). Annuncio • May 01
InfuSystem Holdings, Inc. to Report Q1, 2025 Results on May 08, 2025 InfuSystem Holdings, Inc. announced that they will report Q1, 2025 results Pre-Market on May 08, 2025 Annuncio • Apr 11
Infusystem Holdings, Inc. Announces Ralph Boyd Will Not Stand for Re-Election as Director InfuSystem Holdings, Inc. announced that Ralph Boyd, a current director, will not be standing for re-election. Valuation Update With 7 Day Price Move • Apr 03
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to US$5.03, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 15x in the Healthcare industry in the US. Total loss to shareholders of 45% over the past three years. Annuncio • Apr 03
InfuSystem Holdings, Inc., Annual General Meeting, May 15, 2025 InfuSystem Holdings, Inc., Annual General Meeting, May 15, 2025. Location: meetnow.global/mnmkjmf, United States Annuncio • Apr 01
Infusystem Holdings, Inc Announces CEO Changes, Effective May 19, 2025 InfuSystem Holdings, Inc. announced that Richard Dilorio will be stepping down as the Company’s Chief Executive Officer, effective May 19, 2025. Concurrently, the Company announced that Carrie Lachance, the Company’s President and Chief Operating Officer, and a member of the Company’s board of directors, will assume the role of Chief Executive Officer effective May 19, 2025. Following such date, Mr. Dilorio has agreed to remain available as an advisor to Ms. Lachance, in support of the transition. Recent Insider Transactions Derivative • Mar 12
CEO & Director exercised options and sold US$64k worth of stock On the 7th of March, Richard DiIorio exercised 25.00k options at around US$2.60, then sold 18k of the shares acquired at an average of US$6.18 per share and kept the remainder. For the year to December 2018, Richard's total compensation was 26% salary and 74% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2024, Richard's direct individual holding has decreased from 425.03k shares to 416.66k. Company insiders have collectively sold US$164k more than they bought, via options and on-market transactions in the last 12 months. Valuation Update With 7 Day Price Move • Mar 11
Investor sentiment deteriorates as stock falls 22% After last week's 22% share price decline to US$5.64, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 14x in the Healthcare industry in the US. Total loss to shareholders of 46% over the past three years. Reported Earnings • Mar 04
Full year 2024 earnings: EPS misses analyst expectations Full year 2024 results: EPS: US$0.11 (up from US$0.041 in FY 2023). Revenue: US$134.9m (up 7.2% from FY 2023). Net income: US$2.35m (up 169% from FY 2023). Profit margin: 1.7% (up from 0.7% in FY 2023). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 23%. Revenue is forecast to grow 8.0% p.a. on average during the next 3 years, compared to a 7.1% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Annuncio • Mar 04
InfuSystem Holdings, Inc. Provides Earnings Guidance for the Full Year 2025 InfuSystem Holdings, Inc. provided earnings guidance for the full year 2025. For the period, the company's net revenue growth estimated to be in the 8% to 10% range. Annuncio • Feb 25
InfuSystem Holdings, Inc. to Report Q4, 2024 Results on Mar 04, 2025 InfuSystem Holdings, Inc. announced that they will report Q4, 2024 results Pre-Market on Mar 04, 2025 Board Change • Dec 12
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Ron Hundzinski was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Annuncio • Nov 19
InfuSystem Holdings, Inc. Appoints Ronald Hundzinski to the Board of Directors InfuSystem Holdings, Inc. announced the appointment of Ronald Hundzinski, as an independent director to InfuSystem’s Board of Directors, effective November 12, 2024. Mr. Hundzinski will serve as a director until he stands for election at InfuSystem’s next Annual Shareholders meeting in May 2025. Mr. Hundzinski, 65, retired in 2023 after a distinguished career serving as CFO and other key leadership roles with several public companies. He has been a director at Gentherm, Inc., a thermal management and pneumatic comfort technologies company for the automotive and medical industries, since 2016 and is currently Chairman of the Board at Gentherm. Mr. Hundzinski served as the Chief Financial Officer and an Executive Director of TI Fluid Systems from January 2020 until his retirement in April 2023. Previously, he served as the Executive Vice President of Finance for Tenneco Inc. from January 2018 to December 2019. From 2012 to 2018, Mr. Hundzinski served as the Executive Vice President and Chief Financial Officer of BorgWarner, Inc. During his career with BorgWarner, he held a range of finance leadership positions including Treasurer, Principal Accounting Officer, and Vice President of Finance for the BorgWarner Turbo Systems business. Mr. Hundzinski holds a Bachelor of Business Administration in Finance from Western Michigan University and a Master of Business Administration from the University of Colorado. New Risk • Nov 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 9.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.9x net interest cover). Minor Risk Share price has been volatile over the past 3 months (9.7% average weekly change). Reported Earnings • Nov 09
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Third quarter 2024 results: EPS: US$0.085 (up from US$0.033 in 3Q 2023). Revenue: US$35.3m (up 10% from 3Q 2023). Net income: US$1.81m (up 162% from 3Q 2023). Profit margin: 5.1% (up from 2.1% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.4%. Earnings per share (EPS) also surpassed analyst estimates by 28%. Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 72 percentage points per year, which is a significant difference in performance. Annuncio • Nov 08
Infusystem Holdings, Inc. Provides Revenue Guidance for the Full Year 2024 InfuSystem Holdings, Inc. provided revenue guidance for the full year 2024. For the year, the company expects net revenue growth estimated to be in the high-single-digit range. Recent Insider Transactions Derivative • Nov 06
Insider exercised options and sold US$54k worth of stock On the 31st of October, Addam Chupa exercised options to acquire 9k shares at no cost and sold these for an average price of US$6.19 per share. This trade did not impact their existing holding. Since March 2024, Addam's direct individual holding has increased from 21.02k shares to 24.77k. Company insiders have collectively sold US$317k more than they bought, via options and on-market transactions in the last 12 months. Annuncio • Oct 31
InfuSystem Holdings, Inc. to Report Q3, 2024 Results on Nov 07, 2024 InfuSystem Holdings, Inc. announced that they will report Q3, 2024 results Pre-Market on Nov 07, 2024 Price Target Changed • Aug 13
Price target decreased by 11% to US$14.17 Down from US$15.83, the current price target is an average from 3 analysts. New target price is 113% above last closing price of US$6.66. Stock is down 38% over the past year. The company is forecast to post earnings per share of US$0.12 for next year compared to US$0.041 last year. Reported Earnings • Aug 09
Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Second quarter 2024 results: EPS: US$0.034 (up from US$0.021 in 2Q 2023). Revenue: US$33.7m (up 6.0% from 2Q 2023). Net income: US$717.0k (up 65% from 2Q 2023). Profit margin: 2.1% (up from 1.4% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.6%. Earnings per share (EPS) missed analyst estimates by 18%. Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 101 percentage points per year, which is a significant difference in performance. Annuncio • Aug 08
Infusystem Holdings, Inc. Reaffirms Earnings Guidance for the Full Year 2024 InfuSystem Holdings, Inc. reaffirmed earnings guidance for the full year 2024. For the period, the company's net revenue growth estimated to be in the high-single-digit range. Annuncio • Aug 03
InfuSystem Holdings, Inc. to Report Q2, 2024 Results on Aug 08, 2024 InfuSystem Holdings, Inc. announced that they will report Q2, 2024 results Pre-Market on Aug 08, 2024 Recent Insider Transactions Derivative • Jun 30
CEO & Director exercised options and sold US$142k worth of stock On the 26th of June, Richard DiIorio exercised 50.00k options at around US$2.69, then sold 34k of the shares acquired at an average of US$6.83 per share and kept the remainder. For the year to December 2017, Richard's total compensation was 26% salary and 74% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since September 2023, Richard's direct individual holding has increased from 424.85k shares to 440.12k. Company insiders have collectively sold US$844k more than they bought, via options and on-market transactions in the last 12 months. Board Change • Jun 14
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Ralph Boyd was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Annuncio • May 21
InfuSystem Holdings, Inc. (NYSEAM:INFU) announces an Equity Buyback for $20 million worth of its shares. InfuSystem Holdings, Inc. (NYSEAM:INFU) announces a share repurchase program. Under the program, the company will repurchase up to $20 million worth of its outstanding common shares. The program will be valid till June 30, 2026. Annuncio • May 18
InfuSystem Holdings, Inc. Approves Directorate Elections InfuSystem Holdings, Inc. at its AGM held on May 16, 2024, approved election of Kenneth Eichenbaum and Beverly Huss as directors. Annuncio • May 10
InfuSystem Holdings, Inc. Reaffirms Earnings Guidance for the Full Year 2024 InfuSystem Holdings, Inc. reaffirmed earnings guidance for the full year 2024. For the period, the company's net revenue growth estimated to be in the high-single-digit range. Annuncio • May 03
InfuSystem Holdings, Inc. to Report Q1, 2024 Results on May 09, 2024 InfuSystem Holdings, Inc. announced that they will report Q1, 2024 results Pre-Market on May 09, 2024 Annuncio • Apr 03
InfuSystem Receives Notice from NYSE American Regarding Late Filing of Annual Report on Form 10-K InfuSystem Holdings, Inc. announced that the Company has received notice from the NYSE Regulation (the ‘Notice’) stating that the Company is not in compliance with the continued listing standards of the NYSE American LLC (the ‘Exchange’) under the timely filing criteria included in Section 1007 of the NYSE American Company Guide (the ‘Company Guide’) because the Company failed to timely file its Annual Report on Form 10-K for the year ended December 31, 2023 (the ‘Delinquent Report’), which was due to be filed with the Securities and Exchange Commission (the ‘SEC’) no later than April 1, 2024 (the ‘Filing Delinquency’). The Company has been unable to file the Delinquent Report because, as previously disclosed in the Notification of Late Filing on Form 12b-25 filed by the Company with the SEC on March 14, 2024, the Company requires additional time to complete its procedures to evaluate potential errors related to (i) the classification of certain expenses included in general and administrative costs that should have been included in cost of sales, and (ii) the adoption and ongoing application of Accounting Standards Update No. 2016-02, Leases (Topic 842), referred to as ASC 842. In accordance with Section 1007 of the Company Guide, the Company will have six months from the date of the Filing Delinquency (the ‘Initial Cure Period’), to file the Delinquent Report with the SEC. The Exchange will monitor the Company and the status of the Delinquent Report and any subsequent delayed filings, including through contact with the Company, until the Filing Delinquency is cured. If the Company fails to file the Delinquent Report during the Initial Cure Period, the Exchange may, in its sole discretion, grant an up to six-month additional cure period (the ‘Additional Cure Period’). The Company can regain compliance with the Exchange’s continued listing standards at any time during the Initial Cure Period or Additional Cure Period, as applicable, by filing the Delinquent Report and any subsequent delayed filings with the SEC. If the Exchange determines that an Additional Cure Period is not appropriate, suspension and delisting procedures will commence in accordance with the procedures set out in Section 1010 of the Company Guide. If the Exchange determines that an Additional Cure Period is appropriate and the Company fails to file the Delinquent Report and any subsequent delayed filings by the end of that period, suspension and delisting procedures will generally commence. Notwithstanding the foregoing, however, the Exchange may, in its sole discretion, decide (i) not to afford the Company any Initial Cure Period or Additional Cure Period, as the case may be, at all or (ii) at any time during the Initial Cure Period or Additional Cure Period, to truncate the Initial Cure Period or Additional Cure Period, as the case may be, and immediately commence suspension and delisting procedures if the Company is subject to delisting pursuant to any other provision of the Company Guide, including if the Exchange believes, in the its sole discretion, that continued listing and trading of the Company’s securities on the Exchange is inadvisable or unwarranted in accordance with Sections 1001 through 1006 thereof. The Company intends to regain compliance with the Exchange's continued listing standards. There can be no assurance that the Company will ultimately regain compliance with all applicable Exchange listing standards. Reported Earnings • Mar 15
Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat Full year 2023 results: EPS: US$0.041 (up from US$0.001 in FY 2022). Revenue: US$125.8m (up 14% from FY 2022). Net income: US$872.0k (up US$854.0k from FY 2022). Profit margin: 0.7% (up from 0% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 7.7% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 93 percentage points per year, which is a significant difference in performance. Annuncio • Mar 10
InfuSystem Holdings, Inc. Announces Resignation of R. Rimmy Malhotra as Member of the Board On March 8, 2024, the Board of Directors of InfuSystem Holdings, Inc. accepted the resignation of Mr. R. Rimmy Malhotra as a member of the Board, effective March 8, 2024, pursuant to a cooperation agreement by and among the Company, Mr. Malhotra and Nicoya Capital LLC ("Nicoya"). Mr. Malhotra's resignation is not the product of any disagreement with the Company. Annuncio • Mar 09
InfuSystem Holdings, Inc. to Report Q4, 2023 Results on Mar 14, 2024 InfuSystem Holdings, Inc. announced that they will report Q4, 2023 results at 9:30 AM, US Eastern Standard Time on Mar 14, 2024 New Risk • Nov 08
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.8x net interest cover). Minor Risk Shareholders have been diluted in the past year (2.6% increase in shares outstanding). Annuncio • Nov 01
InfuSystem Holdings, Inc. to Report Q3, 2023 Results on Nov 07, 2023 InfuSystem Holdings, Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 07, 2023 Recent Insider Transactions Derivative • Aug 23
CEO & Director exercised options and sold US$870k worth of stock On the 21st of August, Richard DiIorio exercised 200.00k options at around US$3.18, then sold 109k of the shares acquired at an average of US$11.14 per share and kept the remainder. For the year to December 2016, Richard's total compensation was 39% salary and 61% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since September 2022, Richard's direct individual holding has increased from 256.52k shares to 334.20k. Company insiders have collectively sold US$1.5m more than they bought, via options and on-market transactions in the last 12 months. Major Estimate Revision • Aug 10
Consensus EPS estimates fall by 25%, revenue upgraded The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from US$120.0m to US$122.9m. EPS estimate fell from US$0.06 to US$0.045 per share. Net income forecast to grow 352% next year vs 18% growth forecast for Healthcare industry in the US. Consensus price target up from US$15.17 to US$15.83. Share price rose 14% to US$11.25 over the past week. Annuncio • Aug 04
InfuSystem Holdings, Inc. Revises Earnings Guidance for the Year 2023 InfuSystem Holdings, Inc. revised earnings guidance for the year 2023. The company is providing updated annual guidance for the full year 2023 with net revenue growth estimated to be above the previously stated range of 8% to 10%. Reported Earnings • Aug 04
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Second quarter 2023 results: EPS: US$0.021 (up from US$0.008 loss in 2Q 2022). Revenue: US$31.8m (up 17% from 2Q 2022). Net income: US$435.0k (up US$599.0k from 2Q 2022). Profit margin: 1.4% (up from net loss in 2Q 2022). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 9.1%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 77 percentage points per year, which is a significant difference in performance. Reported Earnings • Aug 04
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Second quarter 2023 results: EPS: US$0.021 (up from US$0.008 loss in 2Q 2022). Revenue: US$31.8m (up 17% from 2Q 2022). Net income: US$435.0k (up US$599.0k from 2Q 2022). Profit margin: 1.4% (up from net loss in 2Q 2022). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 9.1%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 77 percentage points per year, which is a significant difference in performance. Buying Opportunity • Aug 03
Now 20% undervalued Over the last 90 days, the stock is up 9.4%. The fair value is estimated to be US$12.42, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.1% over the last 3 years. Earnings per share has declined by 61%. Revenue is forecast to grow by 17% in 2 years. Earnings is forecast to grow by 7,990% in the next 2 years. Annuncio • Jul 29
InfuSystem Holdings, Inc. to Report Q2, 2023 Results on Aug 03, 2023 InfuSystem Holdings, Inc. announced that they will report Q2, 2023 results Pre-Market on Aug 03, 2023 
